-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

Casi Pharmaceuticals To Run Clinical Trial For Multiple Myeloma Drug In China -- MarketWatch

MarketWatch · 01/06/2023 08:42
For more from MarketWatch: http://www.marketwatch.com/newsviewer

Shares of Casi Pharmaceuticals Inc. (CASI) were up 10% in premarket trading on Friday after the company said China will allow a Phase 1 clinical trial evaluating a multiple myeloma drug developed by the privately held Cleave Therapeutics. The study is expected to start this year. Casi has a subsidiary in Beijing that supports its focus on acquiring and commercializing therapies for the Chinese market. The company's stock is down 73.9% over the past 12 months, while the broader S&P 500 has declined 19.0%.

-Jaimy Lee

(END) Dow Jones Newswires

January 06, 2023 08:42 ET (13:42 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.